Knowledge Ecology International (KEI) delivered the following statement on the WHO roadmap on access to medicines, vaccines and health products (agenda item 5.7.1) on Tuesday evening, 29 January 2019 during the 144th session of WHO’s Executive Board. The WHO Roadmap… Continue Reading
Knowledge Ecology International (KEI) will make the following intervention on agenda item 5.5.3 titled “Preparation for the high-level meeting of the General Assembly on universal health coverage.” Currently, WHO member states are involved in intense negotiations on a draft resolution… Continue Reading
On 18 December 2018, the World Health Organization (WHO) published a “Technical report on Pricing of cancer medicines and its impacts” (hereinafter referred to as the “WHO Cancer Report”). The mandate for the WHO Cancer Report emanates from operative paragraph… Continue Reading
(UPDATE: The NIH provided a response to our comments on February 4, 2019) On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant… Continue Reading
(UPDATE: The NIH provided a response to our comments on January 11, 2019) On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker… Continue Reading
KEI Comments on Medicare Programs: International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Knowledge Ecology International (KEI) is a non-profit organization that focuses on the management of knowledge goods, including new drugs, vaccines and other medical therapies. Much… Continue Reading
The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading
On Monday, 3 December 2018, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 29th Session of the Standing Committee on the Law of Patents (SCP). Thank you Chair. KEI welcomes the conclusions of SCP 28 which call upon… Continue Reading
In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading